Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Mar 12, 2020
Net sales and EBITDA exceeded raised full-year guidance as a result of continued execution of the three strategic growth drivers Etienne Jornod to step down as Executive Chairman. Jacques...
-
Mar 3, 2020
St Gallen, 3 March 2020 - Vifor Pharma today announced that Fitch Ratings (Fitch) has initiated coverage of Vifor Pharma with an investment grade BBB- credit rating and a stable outlook. This...
-
Feb 20, 2020
Partnership brings together Vifor Pharma’s world-class iron deficiency portfolio with Fresenius Kabi’s market-leading patient access in China Gives Vifor Pharma access to largest iron...
-
Feb 17, 2020
St Gallen, 17 February 2020 – Vifor Pharma today announced that it has agreed to purchase a US Food and Drug Administration (FDA) priority review voucher (PRV). A PRV entitles the holder to...
-
Nov 26, 2019
For a fifth consecutive year, Iron Deficiency Day aims to inform about the impact and symptoms of iron deficiency Iron Deficiency Day 2019 encourages people to ‘take iron seriously’ Supported...
-
Nov 26, 2019
Achieved both primary endpoints of clinical remission at weeks 26 and 52 with statistical superiority of avacopan over standard of care at 52 weeks Significantly reduced glucocorticoid toxicity...
-
Nov 18, 2019
St Gallen, 18 November 2019 – Vifor Pharma today announced the appointment of Lee Heeson as President International and member of the Executive Committee as of February 1st, 2020. Lee Heeson...
-
Sep 11, 2019
St Gallen, 11 September 2019 – Vifor Pharma today announced changes to its management. Dr Klaus Henning Jensen will join the company as Chief Medical Officer and Member of the Executive...
-
Sep 9, 2019
St Gallen, 9 September 2019 – Vifor Pharma announced today that Standard & Poor's (S&P) assigned a BBBcredit rating with stable outlook to Vifor Pharma. This inaugural investment grade credit...
-
Sep 4, 2019
Expanded licence creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval The Vifor Pharma Group (SIX: VIFN) and Akebia Therapeutics, Inc....
-
Aug 8, 2019
Strong financial performance in H1 2019 Continued positive performance of all three strategic growth drivers Guidance raised on 2019 net sales and EBITDA On track to achieve Milestone 2020 ZURICH,...
-
Jun 11, 2019
Vifor Pharma and Evotec to create a jointly-owned drug discovery and development platform for innovative nephrology therapeutics Collaboration brings together Evotec’s best-in-class drug...
-
May 26, 2019
Public-private partnership is intended to safeguard Switzerland’s competitive position in pharmaceutical technologies of the future Zurich and Basel, 26 May 2019 Nanopharmaceutics promises...
-
May 21, 2019
ZURICH, 21 May 2019 – Vifor Pharma today announced that treatment of the first patient in their global phase-IIIb DIAMOND study has begun. The study will evaluate the potential of Veltassa® to...
-
May 10, 2019
Veltassa® (patiromer) enables spironolactone for blood pressure management in patients with resistant hypertension and chronic kidney disease by controlling blood potassium levels. ZURICH, 10 May...
-
May 8, 2019
Shareholders agreed to the Board of Directors’ recommendations for all proposed resolutions Election of Dr. Sue Mahony and Kim Stratton and to the Board of Directors Confirmation of all members...
-
Apr 11, 2019
Agreement to jointly commercialise the new diabetic kidney disease (DKD) indication for INVOKANA® (canagliflozin) in the US Only diabetes treatment indicated to slow down the progression of DKD...
-
Mar 14, 2019
VIFOR PHARMA GROUP REPORTS STRONG 2018 RESULTS, EXCEEDING RAISED GUIDANCE THE VIFOR PHARMA GROUP REPORTED A STRONG SALES AND PROFIT PERFORMANCE IN 2018 WITH CONTINUED SOLID GROWTH FROM ITS THREE...
-
Jan 24, 2019
Companies plan to file for full marketing approval to EMA and FDA in 2020 MOUNTAIN VIEW, Calif. and ZURICH, 24 January, 2019 – ChemoCentryx, Inc. and Vifor Fresenius Medical Care Renal Pharma...
-
Jan 22, 2019
Re-analysis of the PIVOTAL data by the investigators has revealed that proactive, high-dose Venofer® compared to reactive, low-dose Venofer® resulted in: Superiority and statistically...
-
Dec 12, 2018
Vifor Pharma Group is pleased to announce the appointment of Patrick Treanor as President of Relypsa on a permanent basis. He is also appointed to the Executive Committee of Vifor Pharma Group...
-
Nov 26, 2018
This year’s Iron Deficiency Day (26 November 2018) aims to raise awareness of the serious public health problems posed by iron deficiency and iron deficiency anaemia and highlight the negative...
-
Oct 29, 2018
PIVOTAL TRIAL CONFIRMS LONG-TERM SAFETY AND EFFICACY OF IV IRON DOSING STRATEGY PIVOTAL TRIAL CONFIRMS LONG-TERM SAFETY AND EFFICACY OF INTRAVENOUS IRON DOSING STRATEGY ALLOWING HIGHER FERRITIN...
-
Sep 20, 2018
Barbara Angehrn joins Vifor Pharma as Chief Business Officer Patrick Treanor takes over from Scott Garland as President of Relypsa Vifor Pharma announced today changes to its management. Barbara...
-
Sep 18, 2018
Vifor Pharma Group increases equity stake in ChemoCentryx from 6.6% to 21.2%. Vifor Pharma Group acquires an additional 7,343,492 common shares of ChemoCentryx, Inc. (NASDAQ: CCXI) from...